ATE207759T1 - Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels - Google Patents

Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels

Info

Publication number
ATE207759T1
ATE207759T1 AT94926591T AT94926591T ATE207759T1 AT E207759 T1 ATE207759 T1 AT E207759T1 AT 94926591 T AT94926591 T AT 94926591T AT 94926591 T AT94926591 T AT 94926591T AT E207759 T1 ATE207759 T1 AT E207759T1
Authority
AT
Austria
Prior art keywords
factor viii
therapeutic agent
activated
deficiency
treating
Prior art date
Application number
AT94926591T
Other languages
English (en)
Inventor
Joseph Edward Curtis
Sam Leland Helgerson
Roger L Lundblad
Shu-Len Liu
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Application granted granted Critical
Publication of ATE207759T1 publication Critical patent/ATE207759T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT94926591T 1993-09-13 1994-08-26 Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels ATE207759T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/120,894 US5576291A (en) 1993-09-13 1993-09-13 Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
PCT/US1994/009613 WO1995007713A1 (en) 1993-09-13 1994-08-26 Activated factor viii as a therapeutic agent and method of treating factor viii deficiency

Publications (1)

Publication Number Publication Date
ATE207759T1 true ATE207759T1 (de) 2001-11-15

Family

ID=22393146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94926591T ATE207759T1 (de) 1993-09-13 1994-08-26 Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels

Country Status (10)

Country Link
US (1) US5576291A (de)
EP (1) EP0719154B1 (de)
JP (1) JPH09502714A (de)
AT (1) ATE207759T1 (de)
AU (1) AU686661B2 (de)
CA (1) CA2168332A1 (de)
DE (1) DE69428905T2 (de)
DK (1) DK0719154T3 (de)
ES (1) ES2166783T3 (de)
WO (1) WO1995007713A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7254894A (en) * 1993-07-23 1995-02-20 Baxter International Inc. Activated human factor viii and method of preparation
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
CA2634663C (en) 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
ATE310533T1 (de) * 1999-07-13 2005-12-15 Zusammensetzungen mit stabilem faktor viii
JP4643783B2 (ja) * 1999-12-24 2011-03-02 一般財団法人化学及血清療法研究所 フォンヴィルブランド因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
RU2357751C2 (ru) 2001-12-21 2009-06-10 Ново Нордиск Хелт Кэр Аг Жидкая композиция полипептидов фактора vii
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
BRPI0311959B8 (pt) 2002-06-21 2021-05-25 Novo Nordisk Healthcare Ag composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
AU2004222625A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
RU2364609C2 (ru) * 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
WO2004112828A1 (en) * 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
AU2004264282B2 (en) 2003-08-14 2010-10-14 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
ATE463572T1 (de) * 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
KR20150138427A (ko) * 2003-12-19 2015-12-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
DE602006018622D1 (de) * 2005-06-30 2011-01-13 Ge Healthcare Bio Sciences Nachweisverfahren für die genexpression
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
JP5401446B2 (ja) * 2007-04-26 2014-01-29 バイエル ヘルスケア エルエルシー 凍結貯蔵を目的とした、組み換えタンパク質溶液の安定化
JP2011502478A (ja) 2007-11-01 2011-01-27 ユニバーシティー オブ ロチェスター 安定性が増大した組換え型第ｖｉｉｉ因子
EP2385825B1 (de) 2008-11-07 2018-10-10 University of Connecticut Faktor-viii-formulierungen
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
EP2822577B1 (de) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Rekombinante faktor-viii-proteine
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
JP6625730B2 (ja) * 2015-05-06 2019-12-25 プレサイエント メディスン ホールディングズ リミテッド ライアビリティ カンパニーＰｒｅｓｃｉｅｎｔ Ｍｅｄｉｃｉｎｅ Ｈｏｌｄｉｎｇｓ， Ｌｌｃ． Ｆｖｉｉｉインヒビター検出のための新規な自動化スクリーニング法の開発
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2460305A2 (fr) * 1979-06-29 1981-01-23 Merieux Inst Procede de preparation d'un concentre de facteur viii
US4386068A (en) * 1980-02-26 1983-05-31 Cutter Laboratories, Inc. Antihemophilic factor concentrate and method for preparation
AT369263B (de) * 1980-08-27 1982-12-27 Immuno Ag Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates
FI841281A7 (fi) * 1983-03-31 1984-10-01 Scripps Clinic And Res Foundation VIII koagulantti-polypeptidien uusi tekijä ja niiden monoklonaaliset vasta-aineet.
US4857635A (en) * 1983-03-31 1989-08-15 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides and monoclonal antibodies tof them
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
US5101016A (en) * 1983-03-31 1992-03-31 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides and monoclonal antibodies to them
US4649132A (en) * 1983-03-31 1987-03-10 Scripps Clinic And Research Foundation Treatment of Factor VIII inhibitors
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
DK525384D0 (da) * 1984-11-05 1984-11-05 Nordisk Insulinlab Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
AU5772886A (en) * 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
US4769336A (en) * 1985-05-24 1988-09-06 Scripps Clinic And Research Foundation Treatment of factor VIII inhibitors
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
CA1331157C (en) * 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
IE69026B1 (en) * 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US4795806A (en) * 1987-07-16 1989-01-03 Miles Laboratories, Inc. Phospholipid affinity purification of Factor VIII:C
US4981951A (en) * 1988-04-14 1991-01-01 Miles Inc. Lectin affinity chromatography of factor VIII
US5149687A (en) * 1991-04-01 1992-09-22 United Technologies Corporation Method for making oriented bismuth and thallium superconductors comprising cold pressing at 700 MPa

Also Published As

Publication number Publication date
JPH09502714A (ja) 1997-03-18
WO1995007713A1 (en) 1995-03-23
AU7638094A (en) 1995-04-03
DE69428905D1 (de) 2001-12-06
US5576291A (en) 1996-11-19
ES2166783T3 (es) 2002-05-01
EP0719154A1 (de) 1996-07-03
DK0719154T3 (da) 2001-11-26
AU686661B2 (en) 1998-02-12
EP0719154B1 (de) 2001-10-31
DE69428905T2 (de) 2002-05-29
CA2168332A1 (en) 1995-03-23

Similar Documents

Publication Publication Date Title
DE69428905D1 (de) Aktivierter faktor viii als ein therapeutisches mittel und verfahren zur behandlung eines faktor viii mangels
ATE275383T1 (de) Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen
ATE280577T1 (de) Oxa-säuren und verwandte verbindungen zur behandlung von störungen der haut
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
DE69807115D1 (de) Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms
DE69734284D1 (de) Zusammensetzung eines polynukleotidvakzins zur behandlung von atemwegs- und fortpflanzungsbezogenen erkrankungen des schweins
LV12558A (lv) Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
ATE230757T1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
ATE444086T1 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln
DE69034148D1 (de) Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie
ATE270553T1 (de) Anwendung von 1,2,4-benzotriazinoxiden zur herstellung eines arzneimittels zur behandlung von tumoren
DE69403969D1 (de) Levobupivacain nützlich zur behandlung von chronischen schmerzen
ATE222488T1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
ATE99932T1 (de) Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
DE68921413D1 (de) Verbindungen und Zusammensetzungen zur Anwendung bei Methoden zur Behandlung und Prophylaxe von Pneumocystis Carinii Pneumonia und anderen Krankheiten.
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE143804T1 (de) Zusammensetzung zur behandlung von mastitis und metritis
DE69523506D1 (de) Verwendung eines Enzyms zur Herstellung eines Mittels für die Behandlung und/oder Prophylaxe von Coccidiose
ATE321045T1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE294582T1 (de) Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee